99-LB: Meta-analysis of Three Real-World, Chart Review Studies to Determine the Effectiveness of FreeStyle Libre Flash Glucose Monitoring System on HbA1c in Adults with Type 2 Diabetes

Three retrospective chart review studies evaluated the effectiveness of the FreeStyle Libre Flash Glucose Monitoring SystemTM on HbA1c when used by adults with type 2 diabetes (T2DM) as their standard of care in a real-world setting. Each study aimed to determine the effect of FreeStyle Libre when used for between 3 months to 6 months on HbA1c. Each study population included adults on a basal-bolus insulin regimen for at least 1 year who had been using FreeStyle Libre regularly for at least 3 months (either self-funded or prescribed) and with HbA1c between 8.0 and 12.0% (64 to 108 mmol/mol). Pregnant patients were excluded, as were patients on dialysis. This meta-analysis comprised of a total of 363 records from insulin using patients with T2DM from 18 medical centres in Austria, France and Germany. On average, HbA1c was 8.9±0.9% (73.3±9.8 mmol/mol) prior to FreeStyle Libre use, age was 63.5±11.0 years and average duration of insulin use 8.3±5.8 years (mean±SD), 67.8% of patients were on oral antidiabetic medications (metformin, SU, TZD, DPP-4 or SGLT2) and 56.4% were male. CVD, renal and retinopathy complications were reported by 36.4%, 33.9% and 19.6% of patients, respectively. HbA1c results were recorded between 90 and 194 days from the start of use of FreeStyle Libre, between January 2015 and August 2018. Overall mean change in HbA1c, after at least 3 months of using FreeStyle Libre, was significantly reduced by 0.9±0.05% (mean±SE); p Disclosure J. Kroeger: Board Member; Self; Abbott. Consultant; Self; Abbott. P. Fasching: None. H. Hanaire: Research Support; Self; Abbott, Eli Lilly and Company, LifeScan, Inc., Novo Nordisk A/S. Other Relationship; Self; Eli Lilly and Company, Novo Nordisk A/S.